Allergy Therapeutics plc (LON:AGY – Get Free Report) shares hit a new 52-week high on Monday . The company traded as high as GBX 12 and last traded at GBX 12, with a volume of 42316 shares traded. The stock had previously closed at GBX 11.25.
Allergy Therapeutics Price Performance
The company has a 50-day moving average of GBX 9.68 and a 200-day moving average of GBX 8.65. The stock has a market capitalization of £687.23 million, a price-to-earnings ratio of -15.54, a P/E/G ratio of -30.70 and a beta of 1.40. The company has a debt-to-equity ratio of 835.48, a quick ratio of 1.48 and a current ratio of 1.63.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.
Featured Articles
- Five stocks we like better than Allergy Therapeutics
- Do not delete, read immediately
- The Crash Has Already Started (Most Just Don’t See It Yet)
- ALERT: Drop these 5 stocks before January 2026!
- [No Brainer Gold Play]: “Show me a better investment.”
- INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
